UBS Group’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4M | Buy |
352,715
+180,884
| +105% | +$2.05M | ﹤0.01% | 3244 |
|
|
2025
Q1 | $1.14M | Sell |
171,831
-6,013
| -3% | -$40K | ﹤0.01% | 4093 |
|
|
2024
Q4 | $1.96M | Buy |
177,844
+99,532
| +127% | +$1.1M | ﹤0.01% | 3728 |
|
|
2024
Q3 | $962K | Sell |
78,312
-39,942
| -34% | -$491K | ﹤0.01% | 3619 |
|
|
2024
Q2 | $1.6M | Buy |
118,254
+78,839
| +200% | +$1.07M | ﹤0.01% | 3035 |
|
|
2024
Q1 | $532K | Buy |
39,415
+9,642
| +32% | +$130K | ﹤0.01% | 4060 |
|
|
2023
Q4 | $157K | Buy |
29,773
+9,498
| +47% | +$50K | ﹤0.01% | 4737 |
|
|
2023
Q3 | $79.9K | Sell |
20,275
-2,806
| -12% | -$11.1K | ﹤0.01% | 4861 |
|
|
2023
Q2 | $245K | Buy |
23,081
+9,004
| +64% | +$95.7K | ﹤0.01% | 4327 |
|
|
2023
Q1 | $117K | Sell |
14,077
-661
| -4% | -$5.51K | ﹤0.01% | 4733 |
|
|
2022
Q4 | $136K | Buy |
14,738
+11,046
| +299% | +$102K | ﹤0.01% | 4699 |
|
|
2022
Q3 | $47K | Buy |
+3,692
| New | +$47K | ﹤0.01% | 5339 |
|
|
2022
Q2 | – | Sell |
-51,941
| Closed | -$1.09M | – | 9715 |
|
|
2022
Q1 | $1.09M | Buy |
51,941
+8,664
| +20% | +$182K | ﹤0.01% | 3150 |
|
|
2021
Q4 | $1.04M | Buy |
43,277
+10,464
| +32% | +$251K | ﹤0.01% | 3421 |
|
|
2021
Q3 | $835K | Buy |
32,813
+28,571
| +674% | +$727K | ﹤0.01% | 3383 |
|
|
2021
Q2 | $143K | Sell |
4,242
-11,073
| -72% | -$373K | ﹤0.01% | 4581 |
|
|
2021
Q1 | $595K | Buy |
+15,315
| New | +$595K | ﹤0.01% | 3808 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7619 |
|
|
2020
Q2 | – | Sell |
-4,380
| Closed | -$100K | – | 7302 |
|
|
2020
Q1 | $100K | Sell |
4,380
-4,769
| -52% | -$109K | ﹤0.01% | 4438 |
|
|
2019
Q4 | $259K | Buy |
9,149
+3,075
| +51% | +$87.1K | ﹤0.01% | 4425 |
|
|
2019
Q3 | $131K | Buy |
6,074
+4,554
| +300% | +$98.2K | ﹤0.01% | 4676 |
|
|
2019
Q2 | $44K | Buy |
+1,520
| New | +$44K | ﹤0.01% | 5175 |
|